SELL and diffuse large B-cell lymphoma: Recently, a few CART19 clinical trials for DLBCL have been conducted in which CART products were manufactured from CD62L+ isolated T cells to generate cellular products enriched for TCM cells (21, 78); however, due to prolonged culture conditions, enrichment for TSCM and TCM subsets in the infused product could not be demonstrated.